NewShape Weight Loss Clinic

NewShape Weight Loss Clinic operates in Houston, TX, providing physician-supervised weight management programs centered on GLP-1 receptor agonist medications including liraglutide, semaglutide, and tirzepatide. The clinic structures its protocols around FDA-approved peptide therapies that regulate appetite, slow gastric emptying, and improve glycemic control in patients with obesity or weight-related metabolic conditions. Each program begins with comprehensive metabolic assessment, body composition analysis, and review of comorbid conditions such as type 2 diabetes, hypertension, or dyslipidemia to determine appropriate medication selection and dosing strategies.

The clinic's GLP-1 programs differentiate between the three available peptides based on patient-specific factors. Liraglutide is administered as a daily subcutaneous injection at doses up to 3.0 mg for weight management, typically prescribed for patients requiring gradual titration or those with prior GLP-1 experience. Semaglutide follows a weekly injection schedule with maintenance doses reaching 2.4 mg, offering convenience for patients seeking less frequent administration. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is dosed weekly up to 15 mg and is often selected for patients with higher baseline BMI or those who have plateaued on single-agonist therapies. NewShape's medical team adjusts peptide selection and dosing based on individual tolerance, weight loss velocity, and metabolic response measured through regular follow-up visits.

Physicians at NewShape Weight Loss Clinic conduct in-person consultations to establish treatment plans, monitor adverse effects such as nausea or gastrointestinal symptoms, and modify protocols as patients progress through weight loss phases. The clinic emphasizes the distinction between weight reduction and metabolic optimization, incorporating laboratory monitoring of HbA1c, lipid panels, and liver function to track improvements beyond scale measurements. Patients receive instruction on proper injection technique, medication storage, and recognition of contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

NewShape structures its patient experience around scheduled in-person visits at its Houston location, where providers perform physical assessments, review food logs, and address barriers to adherence. The clinic does not offer telehealth services, requiring patients to attend appointments for medication dispensing, dose escalation, and safety monitoring. This in-person model allows for direct observation of injection site reactions, real-time blood pressure measurement, and immediate intervention if patients experience severe gastrointestinal side effects or signs of pancreatitis. Follow-up intervals typically occur every four weeks during titration phases and extend to eight-week intervals once patients reach maintenance dosing.

With a 4.8-star rating across 172 Google reviews, NewShape Weight Loss Clinic has established a patient base in the Houston metropolitan area seeking medical oversight for GLP-1 therapy. The clinic's focus remains on peptide-based pharmacotherapy rather than surgical interventions, positioning its services for patients with BMI over 30 or those with BMI over 27 accompanied by weight-related comorbidities. NewShape does not provide bariatric surgery referrals or non-peptide weight loss medications such as phentermine, maintaining a specialized scope limited to GLP-1 and dual-agonist peptide protocols. Patients considering treatment must be prepared for long-term medication use, as discontinuation of GLP-1 therapies typically results in weight regain without sustained lifestyle modifications.